Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone

Llacer Perez, C.Romero Laorden, N.Lozano Mejorada, R.Piulats, J. M.Puente, J.Lorente Estelles, D.Medina, A.Cattrini, C.Vitrone, F. M.Almagro, E.Borrega Garcia, P.Lainez, N.Rivera, L.Villatoro, R.Hernandez, A.Rodriguez-Vida, A.Lopez-Casas, P. P.Gallardo, E.Castro Marcos, E.Olmos Hidalgo, D.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27082enTreatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abirateroneconference outputopen access10.1016/j.annonc.2020.08.8871569-8041http://www.annalsofoncology.org/article/S092375342040883X/pdf573469100625